FOR IMMEDIATE RELEASE

bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., January 3, 2013 – bluebird bio, a leader in the development of potentially transformative one-time gene therapies for severe genetic diseases, announced today that Nick Leschly, chief bluebird, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 9:30 AM PST at the Westin St. Francis Hotel in San Francisco.

About bluebird bio
bluebird bio is developing potentially transformative gene therapies for severe genetic diseases. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s gene therapy platform involves inserting the correct copy of a faulty gene into the patient’s own blood stem cells. bluebird bio’s approach represents the ultimate personalized therapy and a true paradigm shift in the treatment of severe genetic diseases by presenting a potential one-time transformative option for patients. bluebird bio has two clinical-stage programs in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell disease. Led by a world-class team, bluebird bio is privately held and backed by top-tier life sciences investors. Its operations are located in Cambridge, Mass., San Francisco and Paris, France. For more information, please visit http://www.bluebirdbio.com/.

Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com

Investor Contact:
Chris Erdman
MacDougall Biomedical Communications
(781) 235-3060
cerdman@macbiocom.com